CAJ | 학술논문

1型糖尿病以自身免疫性胰岛炎和胰岛β细胞损伤为病理特征.尽管胰岛素强化治疗能使1型糖尿病患者实现良好的血糖控制,但该方案难以完全阻止糖尿病并发症的发生.最大限度的保存1型糖尿病患者自身的胰岛功能,是预防或延缓糖尿病并发症的关键.近年研究显示:自体外周造血干细胞移植(AHSCT)可诱导1型糖尿病患者实现免疫耐受,并改善其胰岛功能.本文将重点介绍采用该方案治疗中国人群初发1型糖尿病患者(多以酮症酸中毒起病)的临床研究结果( NCT01341899,ClinicalTrials.gov),并简要阐述AHSCT治疗1型糖尿病的可能机制和应用前景.
1형당뇨병이자신면역성이도염화이도β세포손상위병리특정.진관이도소강화치료능사1형당뇨병환자실현량호적혈당공제,단해방안난이완전조지당뇨병병발증적발생.최대한도적보존1형당뇨병환자자신적이도공능,시예방혹연완당뇨병병발증적관건.근년연구현시:자체외주조혈간세포이식(AHSCT)가유도1형당뇨병환자실현면역내수,병개선기이도공능.본문장중점개소채용해방안치료중국인군초발1형당뇨병환자(다이동증산중독기병)적림상연구결과( NCT01341899,ClinicalTrials.gov),병간요천술AHSCT치료1형당뇨병적가능궤제화응용전경.
Type 1 diabetes is pathologically characterized by autoimmune insulitis-related islet β-cell destruction.Although intensive insulin therapy for patients with type 1 diabetes can correct hyperglycemia,this therapy does not effectively prevent diabetes-related cardiovascular complications.Hence,preservation of natural β-cell function is critical for the prevention of diabetes-related complications.Receut studies have shown that autologous hematopoietic stem cell transplantation ( A HSCT) is a new promising approach for the treatment of type 1 diabetes by reeonstitution of immunotolerance and preservation of islet β-cell function.Here we introduce the key results of a clinical trial ( NCT 01341899,ClinicalTrials.gov) performed in Chinese type 1 diabetes patients ( most of them with diabetic ketoacidosis at onset ) and discuss the potential mechanisms underlying the action of HSCT and its prospects in the clinical management of type 1 diabetes.